Ok does mould increase mcas symptoms and does it cause dysautonomia

The evidence directly linking mould to MCAS and dysautonomia is thin, but the biological pathway is documented and the clinical overlap is striking.

The retrieved studies do not test whether mould exposure triggers mast cell activation syndrome or dysautonomia in children. What they do show is a plausible mechanism. Fine particulate matter (PM2.5) promotes IgE-mediated mast cell degranulation through a ROS/Gadd45b/JNK signaling pathway [4]. That is a direct molecular link between an inhaled environmental particle and mast cell activation. Separately, a case series found that HPV vaccination could trigger or unmask MCAS in previously undiagnosed individuals, with elevated urinary prostaglandin D2 and plasma heparin [5]. If a vaccine can trigger MCAS, an inhaled fungal toxin with documented immune-activating properties [1] is a biologically plausible trigger as well.

The immune activation from mould is well-documented. People living in moisture-damaged homes have elevated white blood cell counts, higher IL-1β and IL-8 release, and increased TLR-2, TLR-4, and Dectin-1 expression [1]. That is a primed innate immune system, and mast cells are central to that response. A single case report of an atopic child in a water-damaged music school found elevated urine mycotoxins (aflatoxin M1, ochratoxin A, gliotoxin, mycophenolic acid) well above thresholds, while controls had undetectable levels [2]. That shows mycotoxins from indoor mould can enter the body and reach measurable concentrations.

The dysautonomia link is even less directly studied in these records. MCAS itself is known to cause autonomic dysfunction: one case series describes POTS (postural orthostatic tachycardia syndrome) as a consequence of vaccine-triggered MCAS [5]. Another case report documents syncope with hypotension and tachycardia in a patient with mast cell activation disorder [3]. The mechanism is mast cell mediators (histamine, prostaglandin D2, tryptase) directly affecting vascular tone and heart rate. If mould triggers mast cell activation, dysautonomia would be an expected downstream effect.

The evidence here does not include a single study that measured MCAS diagnostic criteria or autonomic function testing in a mould-exposed versus unexposed cohort. That gap matters. But the biological pathway is documented: inhaled particles activate mast cells [4], mould primes the immune system [1], mycotoxins reach the body [2], and MCAS is known to cause dysautonomia [5][3]. For a GP letter to housing, the strongest argument is the documented immune activation from mould [1] combined with the known link between mast cell activation and autonomic dysfunction [5][3]. The direct study has not been done, but the chain is plausible and the respiratory harms are already well-established.

My call: the evidence does not directly prove that mould causes MCAS or dysautonomia, but the biological pathway is documented and the clinical overlap is strong enough to support a GP letter citing immune activation and known mast cell triggers. Confidence: low for the direct causal link, moderate for the plausibility of the mechanism.